ArticleTropical parasitology
Rising case-fatality rate of kala-azar (visceral leishmaniasis) in India: An unexpected challenge to the kala-azar elimination program?
Article in Tropical parasitology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Insights into animal reservoir hosts for the circulation ofOne health (Amsterdam, Netherlands) · 2026Article
- Targeting environmental determinants and settlements in public health planning for the containment of visceral leishmaniasis: a One Health perspective.Frontiers in public health · 2026Article
- mRNA based vaccines and therapeutics for parasitic infections: a comprehensive review.Journal of nanobiotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The target of kala-azar elimination was initially set in 2010 and was later extended several times to finally be fixed in 2020, which also passed without success. However, in 2022, India had come very close to complete elimination by achieving a 98.7% decline in kala-azar cases. While, at the final moments of achieving the long-awaited target of elimination of kala-azar from India, the unexpected rise in the case-fatality rate from 2017 needs to be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.